TJ328B - Interferron conjugates - Google Patents

Interferron conjugates

Info

Publication number
TJ328B
TJ328B TJ97000465A TJ97000465A TJ328B TJ 328 B TJ328 B TJ 328B TJ 97000465 A TJ97000465 A TJ 97000465A TJ 97000465 A TJ97000465 A TJ 97000465A TJ 328 B TJ328 B TJ 328B
Authority
TJ
Tajikistan
Prior art keywords
interferron
conjugates
interferron conjugates
Prior art date
Application number
TJ97000465A
Other versions
TJ97000465A (en
Inventor
Pascal Sebastian Bailon
Alicia Vallejio Palleroni
Original Assignee
Hoffmann La Rjche Ag F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21790006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TJ328(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Rjche Ag F filed Critical Hoffmann La Rjche Ag F
Publication of TJ97000465A publication Critical patent/TJ97000465A/en
Publication of TJ328B publication Critical patent/TJ328B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TJ97000465A 1996-05-31 1997-05-30 Interferron conjugates TJ328B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1883496P 1996-05-31 1996-05-31

Publications (2)

Publication Number Publication Date
TJ97000465A TJ97000465A (en) 1998-12-25
TJ328B true TJ328B (en) 2001-12-24

Family

ID=21790006

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ97000465A TJ328B (en) 1996-05-31 1997-05-30 Interferron conjugates

Country Status (48)

Country Link
US (1) US7201897B2 (en)
EP (1) EP0809996B1 (en)
JP (1) JP2980569B2 (en)
KR (1) KR100254097B1 (en)
CN (1) CN1088721C (en)
AR (1) AR008378A1 (en)
AT (1) ATE235920T1 (en)
AU (1) AU725195B2 (en)
BG (1) BG62273B1 (en)
BR (1) BR9703421A (en)
CA (1) CA2203480C (en)
CO (1) CO4950528A1 (en)
CY (2) CY2433B1 (en)
CZ (1) CZ292775B6 (en)
DE (3) DE809996T1 (en)
DK (1) DK0809996T3 (en)
EG (1) EG24292A (en)
ES (1) ES2110386T3 (en)
GR (1) GR970300063T1 (en)
HK (1) HK1005225A1 (en)
HR (1) HRP970298B1 (en)
HU (1) HU227992B1 (en)
IL (1) IL120902A (en)
IS (1) IS1988B (en)
LU (1) LU91029I2 (en)
MA (1) MA24193A1 (en)
MY (1) MY117909A (en)
NL (1) NL300127I2 (en)
NO (1) NO322964B1 (en)
NZ (1) NZ314903A (en)
OA (1) OA10488A (en)
PA (1) PA8431001A1 (en)
PL (1) PL186949B1 (en)
PT (1) PT809996E (en)
RS (1) RS49533B (en)
RU (1) RU2180595C2 (en)
SA (1) SA97180030B1 (en)
SG (1) SG55314A1 (en)
SI (1) SI0809996T1 (en)
SK (1) SK284458B6 (en)
SV (1) SV1997000049A (en)
TJ (1) TJ328B (en)
TN (1) TNSN97091A1 (en)
TR (1) TR199700358A3 (en)
TW (1) TW517067B (en)
UA (1) UA56989C2 (en)
UY (1) UY24572A1 (en)
ZA (1) ZA974583B (en)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1997016204A1 (en) 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
KR100420642B1 (en) * 1998-03-26 2004-03-02 쉐링 코포레이션 Formulations for protection of peg-interferon alpha conjugates
CZ298579B6 (en) * 1998-04-28 2007-11-14 Applied Research Systems Ars Holding N. V. Polyol and interferon-beta conjugate
SK288038B6 (en) 1998-05-15 2013-01-02 Merck Sharp & Dohme Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
ES2251196T3 (en) * 1998-06-08 2006-04-16 F. Hoffmann-La Roche Ag USE OF PEG-IFN-ALFA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C.
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
MY127276A (en) * 1999-04-08 2006-11-30 Merck Sharp & Dohme Cml therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
HU230057B1 (en) 1999-04-08 2015-06-29 Merck Sharp & Dohme Corp. Melanoma therapy
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
JP2003519478A (en) 2000-01-10 2003-06-24 マキシゲン・ホールディングズ・リミテッド G-CSF conjugate
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
WO2001052882A1 (en) * 2000-01-24 2001-07-26 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
DE60138364D1 (en) 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
EP1282632A1 (en) 2000-04-20 2003-02-12 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
BR0112119A (en) 2000-06-30 2003-05-06 Zymogenetics Inc Isolated polypeptide, isolated nucleic acid molecule, vector, recombinant host cell, method of producing zcyto21 protein, antibody or antibody fragment, method of detecting presence of zcyto21 gene expression in a biological sample
ATE471956T1 (en) * 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd BRANCHED POLYALKYLENE GLYCOLS
MXPA03007619A (en) 2001-02-27 2003-12-04 Maxygen Aps New interferon beta-like molecules.
DE10112825A1 (en) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylation of active ingredients in aqueous solution
ES2291613T3 (en) 2002-01-16 2008-03-01 Biocompatibles Uk Limited CONJUGATES OF POLYMERS.
KR100888371B1 (en) * 2002-01-17 2009-03-13 동아제약주식회사 Antivirus agent comprising bridged co-polymer derivatives and interferon complexes
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
DE10209822A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
AU2003258518B2 (en) 2002-07-24 2007-01-18 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
EP1681303B1 (en) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
CA2496317C (en) 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
ES2214166T1 (en) * 2002-09-11 2004-09-16 Fresenius Kabi Deutschland Gmbh HAS-ILLATED POLYPEPTIDES, ESPECIALLY, HAS-ILADA ERIPTROPOYETINA.
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
AU2003297285A1 (en) * 2002-11-18 2004-06-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP2263684A1 (en) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 derivatives
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
CN100355784C (en) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 Method for preparing polyethylene glycol-modified alpha-interferon 1b
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
TW200611910A (en) * 2004-05-19 2006-04-16 Maxygen Inc Interferon-alpha polypeptides and conjugates
KR20070034512A (en) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 New Antigen-Binding Polypeptides and Uses thereof
JP2008509889A (en) * 2004-06-30 2008-04-03 イージェン コーポレーション PEGylated interferon alpha-1b
CN101039660B (en) 2004-08-12 2010-10-06 先灵公司 Stable pegylated interferon formulation
CN103690936A (en) 2004-12-22 2014-04-02 Ambrx公司 Modified human growth hormone
WO2006102659A2 (en) * 2005-03-23 2006-09-28 Nektar Therapeutics Al, Corporation CONJUGATES OF AN hGH MOIETY AND A POLYMER
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
EP1901777A2 (en) * 2005-06-20 2008-03-26 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon-alpha analogs and interferon tau
JP4261531B2 (en) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ Lactoferrin complex and method for producing the same
AU2006315347A1 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
CN101002944B (en) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 Conjugate of branched chair polymacrogol-interferon, and its preparing method
CN101002945B (en) 2006-01-20 2012-09-05 清华大学 Novel complex used for treating tumor
CN100475270C (en) 2006-01-20 2009-04-08 清华大学 Medicine for treating tumor, and application thereof
AU2007250739A1 (en) 2006-05-16 2007-11-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treating or preventing HCV infection
BRPI0712008A2 (en) 2006-05-24 2012-01-10 Novo Nordisk Healthcare Ag extended fix derivatives and analogs
WO2008030613A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CN1966547B (en) * 2006-11-06 2011-11-09 中国药科大学 Double-chain structured polyethylene glycol derivative preparation and its combination with pharmaceutical molecule
JP5541594B2 (en) * 2006-11-07 2014-07-09 ディーエスエム アイピー アセッツ ビー．ブイ． Carbamates, thiocarbamates or carbamides containing biomolecular moieties
KR101079993B1 (en) 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CN101219219B (en) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 Complex containing vascellum chalone or fragment, preparation method and application thereof
JP5515224B2 (en) 2007-02-28 2014-06-11 日油株式会社 Multi-branched polyoxyalkylene derivatives
WO2008121563A2 (en) 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
CA2698173C (en) 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
CA2698396C (en) 2007-09-04 2014-01-21 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
KR20100103595A (en) * 2008-01-18 2010-09-27 에프. 호프만-라 로슈 아게 Purification of non-glycosylated proteins
PT2237799T (en) * 2008-02-01 2019-07-05 Ascendis Pharma As Prodrug comprising a self-cleavable linker
CN103694337B (en) 2008-02-08 2016-03-02 Ambrx公司 Modified leptin polypeptide and its purposes
MX2010010953A (en) 2008-04-03 2011-04-21 Biosteed Gene Expression Tech Co Ltd Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof.
SI3050576T1 (en) 2008-04-29 2021-08-31 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
US8143412B2 (en) 2008-07-08 2012-03-27 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
EP3225248B1 (en) 2008-07-23 2023-06-07 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
CA2737026C (en) 2008-09-26 2019-12-24 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
CA2738033C (en) 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
IT1399351B1 (en) 2009-06-16 2013-04-16 Fidia Farmaceutici PROCEDURE FOR THE SYNTHESIS OF GLYCOSAMINOGLICAN CONJUGATES (GAG) WITH BIOLOGICALLY ACTIVE MOLECULES, POLYMERIC CONJUGATES AND RELATIVE USES
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
CN102596201A (en) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
CN104017063A (en) 2009-12-21 2014-09-03 Ambrx公司 Modified porcine somatotropin polypeptides and their uses
MX349301B (en) 2009-12-21 2017-07-21 Ambrx Inc Modified bovine somatotropin polypeptides and their uses.
EP2542569B1 (en) 2010-03-05 2020-09-16 Omeros Corporation Chimeric inhibitor molecules of complement activation
JP2013528374A (en) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Polypeptide inhibitors of VLA4
CN103096891A (en) 2010-06-24 2013-05-08 判米德有限公司 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
RU2447083C1 (en) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
DK2605789T3 (en) 2010-08-17 2019-09-16 Ambrx Inc MODIFIED RELAXIN POLYPEPTIDES AND APPLICATIONS THEREOF
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CN102229667A (en) * 2011-06-03 2011-11-02 北京伟嘉人生物技术有限公司 Polyethylene glycol modified porcine alpha-interferon, preparation method and application thereof
KR20140054009A (en) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 Relaxin fusion polypeptides and uses thereof
KR20140063657A (en) 2011-08-03 2014-05-27 사이세리스 Hcv immunotherapy
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
JP2015512900A (en) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy to treat HCV infection in a special patient genotype subpopulation
SI2859017T1 (en) 2012-06-08 2019-05-31 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
ES2728864T3 (en) 2012-08-31 2019-10-29 Sutro Biopharma Inc Modified amino acids comprising an azido group
EA022617B1 (en) * 2013-03-28 2016-02-29 Илья Александрович МАРКОВ Monopegylated interferon-alpha of branched structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity
EA021610B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Liquid antiviral formulation
EA023323B1 (en) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Branched acyl azide pegylating agent, method for preparing the same and method for preparing pegylated interferon
ES2865473T3 (en) 2013-07-10 2021-10-15 Sutro Biopharma Inc Antibodies Comprising Multiple Site-Specific Unnatural Amino Acid Residues, Methods for Their Preparation, and Methods of Use
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2554761C1 (en) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Anti-enteroviral and immunostimulating agent
MX2017004947A (en) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof.
SI3215193T1 (en) 2014-11-06 2024-02-29 Pharmaessentia Corporation Dosage regimen for pegylated interferon
EP3988083A1 (en) 2014-11-21 2022-04-27 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
EP3370759A1 (en) 2015-11-03 2018-09-12 H. Hoffnabb-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and an interferon
CN106749608B (en) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 Interferon alpha conjugates
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
KR102670432B1 (en) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 Modified relaxin polypeptides containing pharmacokinetic enhancers and uses thereof
RU2678332C1 (en) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
KR20210057124A (en) 2018-09-11 2021-05-20 암브룩스, 인코포레이티드 Interleukin-2 polypeptide conjugate and use thereof
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
AU2020223031A1 (en) 2019-02-12 2021-08-19 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
CN115243726A (en) 2020-03-11 2022-10-25 北京泰德制药股份有限公司 Interleukin-2 polypeptide conjugates and methods of use thereof
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
MX2023011480A (en) 2021-04-03 2023-12-06 Ambrx Inc Anti-her2 antibody-drug conjugates and uses thereof.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681848A (en) 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
WO1984004745A1 (en) 1983-05-31 1984-12-06 Takeda Chemical Industries Ltd Novel polypeptides and their use
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (en) 1985-06-26 1991-02-07 Cetus Corp SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION.
DE3719046A1 (en) 1987-06-06 1988-12-15 Basf Ag USE OF SALTS OF SULFONAMIDE CARBONIC ACIDS AS CORROSION INHIBITORS IN AQUEOUS SYSTEMS
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5145773A (en) * 1989-05-25 1992-09-08 Sloan-Kettering Institute For Cancer Research Method to detect sensitivity to alpha-interferon therapy
EP0400472B1 (en) * 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
US5238915A (en) 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9111967D0 (en) 1991-06-04 1991-07-24 Erba Carlo Spa 2,5'-nucleotide analogs as antiviral agents
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0730470B1 (en) * 1993-11-10 2002-03-27 Enzon, Inc. Improved interferon polymer conjugates
AU1916295A (en) * 1994-02-08 1995-08-29 Amgen, Inc. Oral delivery of chemically modified proteins
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (en) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay

Also Published As

Publication number Publication date
AU725195B2 (en) 2000-10-05
NO972480D0 (en) 1997-05-30
NO972480L (en) 1997-12-01
TJ97000465A (en) 1998-12-25
PL186949B1 (en) 2004-04-30
TNSN97091A1 (en) 2005-03-15
IL120902A0 (en) 1997-09-30
CA2203480A1 (en) 1997-11-30
GR970300063T1 (en) 1998-01-30
SI0809996T1 (en) 2003-08-31
SG55314A1 (en) 1998-12-21
HRP970298A2 (en) 1998-04-30
MA24193A1 (en) 1997-12-31
HRP970298B1 (en) 2003-08-31
NZ314903A (en) 1998-10-28
UY24572A1 (en) 2000-12-29
HUP9700959A3 (en) 1998-03-30
DE10399018I1 (en) 2003-10-23
MY117909A (en) 2004-08-30
UA56989C2 (en) 2003-06-16
ATE235920T1 (en) 2003-04-15
PT809996E (en) 2003-06-30
TR199700358A2 (en) 1997-12-21
BG101540A (en) 1998-02-27
AR008378A1 (en) 2000-01-19
EP0809996B1 (en) 2003-04-02
HUP9700959A2 (en) 1998-03-02
CO4950528A1 (en) 2000-09-01
EG24292A (en) 2009-01-08
CY2433B1 (en) 2004-11-12
CN1088721C (en) 2002-08-07
CZ167997A3 (en) 1997-12-17
DK0809996T3 (en) 2003-07-21
CY2005006I1 (en) 2009-11-04
NL300127I2 (en) 2003-09-01
JPH1067800A (en) 1998-03-10
CN1167777A (en) 1997-12-17
LU91029I2 (en) 2004-01-23
IS1988B (en) 2005-02-15
PL320251A1 (en) 1997-12-08
HK1005225A1 (en) 1998-12-31
EP0809996A2 (en) 1997-12-03
YU17597A (en) 1999-07-28
IL120902A (en) 2004-06-20
NL300127I1 (en) 2003-07-01
HU9700959D0 (en) 1997-07-28
DE69720320T2 (en) 2004-06-03
ES2110386T3 (en) 2003-10-01
MX9704012A (en) 1997-11-29
CZ292775B6 (en) 2003-12-17
DE69720320D1 (en) 2003-05-08
KR970074791A (en) 1997-12-10
SA97180030B1 (en) 2005-11-12
RS49533B (en) 2006-12-15
CA2203480C (en) 2009-06-30
RU2180595C2 (en) 2002-03-20
HU227992B1 (en) 2012-08-28
NO322964B1 (en) 2006-12-18
PA8431001A1 (en) 2000-05-24
OA10488A (en) 2002-04-11
EP0809996A3 (en) 1999-04-14
ZA974583B (en) 1998-11-17
DE809996T1 (en) 1998-04-09
CY2005006I2 (en) 2009-11-04
SV1997000049A (en) 1998-07-09
TR199700358A3 (en) 1997-12-21
US7201897B2 (en) 2007-04-10
BG62273B1 (en) 1999-07-30
TW517067B (en) 2003-01-11
SK67397A3 (en) 1997-12-10
ES2110386T1 (en) 1998-02-16
US20040030101A1 (en) 2004-02-12
BR9703421A (en) 1998-09-15
KR100254097B1 (en) 2000-05-01
IS4491A (en) 1997-12-01
SK284458B6 (en) 2005-04-01
AU2372397A (en) 1997-12-04
JP2980569B2 (en) 1999-11-22

Similar Documents

Publication Publication Date Title
TJ328B (en) Interferron conjugates
GB9713980D0 (en) New conjugates
DE69634986D1 (en) Modulares wandlersystem
DE59704951D1 (en) Plättchenförmiges titandioxidpigment
DE69715838D1 (en) Thermomorphe drucksensitive klebmittel
DE69608577D1 (en) Thermostabiler schalldämmstoff
DE69711882D1 (en) Carbolinderivate
DE69702926D1 (en) Polyurethanhartschäume
DE69705420D1 (en) Polyurethanhartschäume
DE69708059D1 (en) Thiophenopyrimidine
DE59705192D1 (en) Lcp-blends
DE59711450D1 (en) Arylalkanoylpyridazine
DE69703480D1 (en) Anionische photokatalysator
DE59700372D1 (en) Blockcopolymere
DE69621466D1 (en) Thermoplastische hydroxy-phenoxyetherpolymerverbundwerkstoffe
DE69710573D1 (en) Morpholinyl-anthracyclinderivate
DE59707730D1 (en) Peripheralpumpe
IL116456A0 (en) Oligonucleotide-dendrimer conjugates
DE59704086D1 (en) Twin-dualmode-filter
DE59703905D1 (en) Linearmotorgetriebene transportanlage
DE59711583D1 (en) Heterocyclyluracile
DE59703023D1 (en) Cyclopeptidderivate
DE59702027D1 (en) Bragg-modulator
DE59709914D1 (en) Substituierte aromatische phosphonsäurederivate
DE59705556D1 (en) Peripheralpumpe